LUVOX Drug Patent Profile

Which patents cover Luvox, and when can generic versions of Luvox launch?

Luvox is a drug marketed by Ani Pharms, Solvay, and Jazz Pharms. and is included in three NDAs.

The generic ingredient in LUVOX is fluvoxamine maleate. There are eleven drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the fluvoxamine maleate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Luvox

A generic version of LUVOX was approved as fluvoxamine maleate by AIPING PHARM INC on November 29^th, 2000.

Summary for LUVOX

US Patents:	0
Applicants:	3
NDAs:	3

US Patents and Regulatory Information for LUVOX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ani Pharms	LUVOX	fluvoxamine maleate	TABLET;ORAL	021519-001	Dec 20, 2007	AB	RX	Yes	No
Solvay	LUVOX	fluvoxamine maleate	TABLET;ORAL	020243-004	Dec 5, 1994		DISCN	Yes	No
Solvay	LUVOX	fluvoxamine maleate	TABLET;ORAL	020243-001	Dec 5, 1994		DISCN	Yes	No
Jazz Pharms	LUVOX CR	fluvoxamine maleate	CAPSULE, EXTENDED RELEASE;ORAL	022033-001	Feb 28, 2008		DISCN	Yes	No
Ani Pharms	LUVOX	fluvoxamine maleate	TABLET;ORAL	021519-002	Dec 20, 2007	AB	RX	Yes	No
Ani Pharms	LUVOX	fluvoxamine maleate	TABLET;ORAL	021519-003	Dec 20, 2007	AB	RX	Yes	No

International Patents for LUVOX

See the table below for patents covering LUVOX around the world.

Country	Patent Number	Title	Estimated Expiration
German Democratic Republic	128332	VERFAHREN ZUR HERSTELLUNG VON VERBINDUNGEN MIT ANTIDEPRESSIVER WIRKUNG
Belgium	839744
Switzerland	626057
Austria	342568
Italy	1063064	COMPOSTI AVENTI ATTIVITA ANTIDEPRESSIVA A BASE DI ETERI OSSIMICI DERIVATI DA FENILCHETONI
Switzerland	629477	VERFAHREN ZUR HERSTELLUNG NEUER OXIMAETHERVERBINDUNGEN.

LUVOX Market Analysis and Financial Projection

Last updated: February 3, 2026

What is LUVOX and Its Therapeutic Use?

LUVOX is the brand name for fluvoxamine maleate, an SSRI (selective serotonin reuptake inhibitor) primarily approved for treating obsessive-compulsive disorder (OCD). It is marketed by Takeda Pharmaceuticals, with approvals also for depression and social anxiety in some markets.[1]

How Does LUVOX Fit Into the Pharmaceutical Market Landscape?

The global antidepressant market was valued at approximately $14.8 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of around 3.5% through 2027.[2] Fluvoxamine accounts for a small but significant share, mainly driven by OCD and off-label use during the COVID-19 pandemic for its potential anti-inflammatory effects.[3]

What Are the Patent and Regulatory Statuses Impacting Investment?

• Patent Status: LUVOX’s primary patents have expired or are nearing expiration in major markets, including the US and EU, typically around 2005-2010. No new patents are filed for the formulation or use indications, limiting exclusivity prospects.
• Regulatory Approvals: It remains authorized for OCD in over 40 countries, with some jurisdictions adding indications for depression. Protracted regulatory processes in emerging markets may delay market penetration.[4]

What Are the Key Drivers and Risks?

Drivers:

• Market Demand: Continues to be driven by OCD diagnosis rates, which have increased globally, partly due to increased awareness and mental health advocacy.[5]
• Off-Label Use: Uptake during COVID-19 for treating mild to moderate symptoms of infection has temporarily increased demand, though regulatory authorities might restrict such off-label use.
• Generic Competition: As patents have expired, multiple generic versions of fluvoxamine exist, reducing pricing power but enlarging market access.

Risks:

• Generic Entrant Competition: Price erosion due to generics reduces margins.
• Limited Patent Protection: No new formulation patents mean limited exclusivity.
• Competitive APIs: Major competitors like sertraline and fluoxetine are entrenched in the market with broader label indications.
• Regulatory and Reimbursement: Variability in approval processes and reimbursement policies across regions.

What Are the Financial and R&D Investment Outlooks?

• Market Penetration: Growth heavily depends on incremental adoption within existing OCD treatment paradigms.
• R&D Pipeline: Takeda is pursuing novel indications and combination therapies, but no significant pipeline assets targeting fluvoxamine have announced breakthroughs.
• Pricing Models: With no patent protection, price competition is fierce, with average prices for generics ranging from $0.10 to $0.50 per tablet.[6]

How Does Competition Impact Investment?

The presence of multiple generics lowers barriers for new entrants, pressuring prices. Top competitors include Sertraline (Zoloft), fluoxetine (Prozac), and others with broader approval scopes. Limited patent protection reduces potential for premium pricing. However, off-label and emerging indications could provide niche growth if supported by clinical evidence.

What Are the Key Geographies for Growth and Investment?

• United States: Large market with extensive prescription volumes; recent off-label interest for COVID-19 treatment could create short-term demand.
• European Union: Established prescribing habits; regulatory pathways are well-defined.
• Emerging Markets: Growth potential exists but hampered by complex regulatory environments and affordability issues.

Summarized Investment Recommendations

• Short Term: High uncertainty due to patent expiration and generic competition. Potential upside from off-label COVID-19 related use but limited by regulatory restrictions.
• Medium to Long Term: Investment value hinges on new clinical indications, unique formulation technology, or combination uses that could extend exclusivity or create niche markets.
• R&D Outlook: Limited unless breakthrough clinical data supports expanded indications. No significant pipeline breakthroughs anticipated soon.

Key Takeaways

• LUVOX’s market outlook depends on increases in OCD diagnosis and off-label COVID-19 applications.
• Patent expirations mean limited exclusivity, increasing reliance on competitive advantages like clinical differentiation or niche indications.
• Generic competition constrains pricing and margins, requiring innovation or unique formulations to sustain profitability.
• Geographic expansion, especially into emerging markets, offers growth but comes with regulatory hurdles.
• R&D investments targeted at new indications or delivery methods could create future value but are currently limited.

FAQs

1. What are the main competitors to LUVOX?
Sertraline (Zoloft) and fluoxetine (Prozac) are the leading SSRI competitors, with broader approved indications and entrenched market positions.

2. Is LUVOX still under patent protection?
No. Primary patents expired in the 2000s, leaving the drug open to generic competition.

3. What potential future uses could drive LUVOX’s growth?
Emerging research suggests possible benefits for COVID-19, depression, and other neuropsychiatric conditions, but regulatory approval is pending or limited.

4. How does off-label use impact the drug’s revenue?
Off-label use can temporarily boost sales but carries regulatory risks and lacks approval for such indications.

5. What are the main regulatory hurdles for LUVOX?
Approval processes vary internationally; some markets face delays or restrictions on off-label use. No recent approvals for new indications have been granted.

---

References
[1] Takeda Pharmaceuticals, LUVOX product information.
[2] GlobalData, "Antidepressant Market Analysis," 2022.
[3] FDA, COVID-19 treatment considerations, 2021.
[4] European Medicines Agency, regulatory status of LUVOX.
[5] WHO Mental Health Data 2022.
[6] Drugs.com, generic pricing data.